Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics
Hämostaseologie · 01.08.2024 · 44 (04) · 316-325
DOI: 10.1055/a-2247-4209 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.08.2024. Verfasst von Jennifer Gebetsberger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Receptors, Thrombopoietin, Thrombopoietin, Receptors, Fc, Recombinant Fusion Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 96 Literaturangaben.
Abstract (Originalsprache)
This review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for pediatric patients. Romiplostim and eltrombopag are already established as second-line treatment for persistent or chronic immune thrombocytopenia (ITP). As in adults, TPO-RAs are currently also evaluated in severe aplastic anemia (SAA), chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), and poor engraftment after hematopoietic stem cell transplantation in pediatric and adolescent patients. Moreover, studies on the implication of TPO-RA in treating rare inherited thrombocytopenias, such as Wiskott-Aldrich syndrome (WAS), congenital amegakaryocytic thrombocytopenia (CAMT), or MYH9-associated thrombocytopenia, deserve future attention. Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Neonatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Zitieren
APA
Gebetsberger, J., Streif, W., & Dame, C. (2024). Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. Hämostaseologie, 44(04), 316-325. https://doi.org/10.1055/a-2247-4209
Vancouver
Gebetsberger J, Streif W, Dame C. Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. Hämostaseologie. 2024;44(04):316-325. doi:10.1055/a-2247-4209
BibTeX
@article{Gebetsberger2024,
author = {Gebetsberger, Jennifer and Streif, Werner and Dame, Christof},
title = {Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics},
journal = {Hämostaseologie},
year = {2024},
volume = {44},
number = {04},
pages = {316--325},
doi = {10.1055/a-2247-4209}
}
EUVIMED